Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)
Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Martin J. van den Bent(Erasmus MC Cancer Institute), Filip De Vos(University Medical Center Utrecht), Martin Klein(Amsterdam University Medical Centers), Corneel Coens(European Organisation for Research and Treatment of Cancer), Abigirl Machingura(European Organisation for Research and Treatment of Cancer), Paul Mulholland(University College London Hospitals NHS Foundation Trust), Martin Taphoorn(Leiden University Medical Center), Wolfgang Wick(German Cancer Research Center), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Andrew Bottomley(European Organisation for Research and Treatment of Cancer), Joanne Lewis(Freeman Hospital), Irina Ghislain(European Organisation for Research and Treatment of Cancer), Paul M. Clément(Universitair Ziekenhuis Leuven), Vassilis Golfinopoulos(Champalimaud Foundation), Walter Taal(Heidelberg University)
Cited by 13
Related Papers
EORTC QLQ-C30 Scoring Manual
|Research at the University of Copenhagen (University of Copenhagen)|1995|2.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k